GoodRx is monitoring seven potential FDA drug approvals in 2025 ... Boston-based Vertex Pharmaceuticals anticipates a potential approval for suzetrigine. If approved, it would be the first new ...

On January 6, the FDA announced the availability of draft guidance on accelerated approval for drugs and biological products, and consideration ...

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

While President-elect Donald Trump isn't new to the White House, most of his proposed Cabinet appointees are. The Cabinet ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for ZW20 ...

Boston Scientific stock popped Wednesday after the medtech giant agreed to full acquire Bolt Medical for up to $900 million.

The US Food and Drug Administration (FDA) has announced a final rule expanding the approval pathway for nonprescription drug ...

The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

The DEA rejected a September request from Colorado officials to participate in the United States' historic marijuana ...